<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02342158</url>
  </required_header>
  <id_info>
    <org_study_id>PERMED01-IPC 2014-003</org_study_id>
    <nct_id>NCT02342158</nct_id>
  </id_info>
  <brief_title>Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors</brief_title>
  <acronym>PERMED01</acronym>
  <official_title>Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors-PERMED01-IPC 2014-003</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research Center of Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PERMED01 is a prospective monocenter clinical trial which aims to evaluate the number
      patients with locally advanced or metastatic cancer for whom identification of molecular
      alterations in tumor samples can lead to the delivery of a targeted therapy. PERMED01 will
      enroll 460 patients in 3 years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of screened patients in whom a molecular abnormality for which a targeted therapy exists</measure>
    <time_frame>4-6 weeks after biopsy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular Characterization of locally advanced and metastatic malignancies using next generation sequencing</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full exome and transcriptome sequencingof locally advanced and metastatic tumours</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating tumor DNA detection and characterization in locally advanced and metastatic disease</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Tumor Cells (CTC) detection and characterization in breast cancer</measure>
    <time_frame>3.5 years</time_frame>
    <description>Comparison of three distinct methods for the CTC detection in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preclinical predictive clinical models validation (limited to breast cancer)</measure>
    <time_frame>4 years</time_frame>
    <description>Patient-derived tumour xenograft models (PDX), drug sensitivity tests in vitro</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Locally advanced /metastatic cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy or surgical sampling</intervention_name>
    <arm_group_label>Locally advanced /metastatic cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <arm_group_label>Locally advanced /metastatic cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;18 years

          -  Histological diagnosis of cancer

          -  Locally advanced or metastatic, biopsiable disease

          -  ECOG Performans Status ≤2

          -  Affiliation to social security

          -  Signed informed consent.

        Exclusion Criteria:

          -  Emergency, Individually deprived of liberty or placed under the authority of a tutor

          -  Patients with symptomatic or progressive brain metastasis

          -  Patients who have only bone and/or brain metastases

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dominique GENRE, MD</last_name>
    <phone>+33491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jihane PAKRADOUNI, PharmD PhD</last_name>
    <phone>+33491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique GENRE, MD</last_name>
      <phone>0033491223778</phone>
      <email>drci.ip@ipc.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jihane PAKRADOUNI, PharmD PhD</last_name>
      <phone>0033491223778</phone>
      <email>drci.ip@ipc.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>François BERTUCCI, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony GONCALVES, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gwenaelle GRAVIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2014</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <last_update_submitted>June 27, 2016</last_update_submitted>
  <last_update_submitted_qc>June 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

